MX9800922A - Quinolonas y su uso terapeutico. - Google Patents

Quinolonas y su uso terapeutico.

Info

Publication number
MX9800922A
MX9800922A MX9800922A MX9800922A MX9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A
Authority
MX
Mexico
Prior art keywords
quinolones
therapeutic use
quinolone
carboxamides
phosphodiesterase
Prior art date
Application number
MX9800922A
Other languages
English (en)
Inventor
Steven Colin Beasley
John Gary Montana
Hazel Joan Dyke
Alan Findlay Haughan
Karen Ann Runcie
David Thomas Manallack
George Martin Buckley
Robert James Maxey
Hannah Jayne Kendall
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515811.9A external-priority patent/GB9515811D0/en
Priority claimed from GBGB9526377.8A external-priority patent/GB9526377D0/en
Priority claimed from GBGB9605868.0A external-priority patent/GB9605868D0/en
Priority claimed from GBGB9611898.9A external-priority patent/GB9611898D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of MX9800922A publication Critical patent/MX9800922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)

Abstract

1-alquil-substituido-quinolona-3-carboxamidas tienen utilidad terapéutica vía inhibicion de la actividad de la Fosfodiesterasa IV esterasa y/o del Factor de necrosis Tumoral.
MX9800922A 1995-08-02 1996-08-02 Quinolonas y su uso terapeutico. MX9800922A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9515811.9A GB9515811D0 (en) 1995-08-02 1995-08-02 Novel compounds
GBGB9526377.8A GB9526377D0 (en) 1995-12-22 1995-12-22 Novel compounds
GBGB9605868.0A GB9605868D0 (en) 1996-03-20 1996-03-20 Novel compounds
GBGB9611898.9A GB9611898D0 (en) 1996-06-07 1996-06-07 Quinolones and their therapeutic use
PCT/GB1996/001862 WO1997004779A1 (en) 1995-08-02 1996-08-02 Quinolones and their therapeutic use

Publications (1)

Publication Number Publication Date
MX9800922A true MX9800922A (es) 1998-05-31

Family

ID=27451319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800922A MX9800922A (es) 1995-08-02 1996-08-02 Quinolonas y su uso terapeutico.

Country Status (12)

Country Link
US (1) US5891878A (es)
EP (1) EP0841929B1 (es)
JP (1) JPH11513021A (es)
AT (1) ATE239477T1 (es)
AU (1) AU696390B2 (es)
CA (1) CA2225552A1 (es)
DE (1) DE69628019T2 (es)
DK (1) DK0841929T3 (es)
ES (1) ES2193252T3 (es)
MX (1) MX9800922A (es)
PT (1) PT841929E (es)
WO (1) WO1997004779A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
NZ505362A (en) * 1997-12-22 2004-12-24 Upjohn Co 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US6248739B1 (en) * 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
US6458788B1 (en) 2000-03-21 2002-10-01 Pharmacia & Upjohn Company 4-hydroxycinnoline-3-carboxyamides as antiviral agents
MXPA02009251A (es) 2000-03-21 2004-04-05 Upjohn Co 4-oxo-1,4-dihidro-3-cinolincarboxamidas como agentes antivirales.
CA2399991A1 (en) 2000-03-21 2001-09-27 Pharmacia & Upjohn Company 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
CN1416430A (zh) 2000-03-21 2003-05-07 法玛西雅厄普约翰美国公司 作为抗病毒药的4－氧－1,4－二氢[1,8]－二氮杂萘－3－甲酰胺类
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2002070487A1 (en) 2001-03-01 2002-09-12 Pharmacia & Upjohn Company Substituted quinolinecarboxamides as antiviral agents
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
ATE353907T1 (de) * 2002-04-01 2007-03-15 Univ Florida Steroidische chinole als antioxidantien-vorstufen
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
WO2004069248A1 (en) * 2002-12-09 2004-08-19 University Of Florida Prodrugs for use a ophthalmic agents
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
CN100471842C (zh) 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
SI2502911T1 (sl) * 2004-06-24 2017-07-31 Vertex Pharmaceuticals Incorporated Modulatorji transporterjev ATP vezavne kasete
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
RU2556984C2 (ru) * 2004-06-24 2015-07-20 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
DE102004035203A1 (de) 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
DE102005030524A1 (de) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituierte Chinolone II
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
EP1974212A1 (en) * 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
LT1993360T (lt) * 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
KR101419554B1 (ko) * 2006-03-13 2014-07-17 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ­３ 억제제로서 아미노퀴놀론
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
NZ592685A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107998131B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯类化合物用于制备抗adv-7病毒药物
CN111646941A (zh) * 2020-07-17 2020-09-11 天津科技大学 一种磺酰胺类衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524558A (en) * 1967-03-30 1970-08-18 American Mach & Foundry Cargo loading means and method
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
FR2564832B1 (fr) * 1984-05-23 1987-05-15 Panmedica Sa Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02124871A (ja) * 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体

Also Published As

Publication number Publication date
DE69628019T2 (de) 2004-01-22
US5891878A (en) 1999-04-06
CA2225552A1 (en) 1997-02-13
DK0841929T3 (da) 2003-09-01
PT841929E (pt) 2003-09-30
DE69628019D1 (de) 2003-06-12
ES2193252T3 (es) 2003-11-01
ATE239477T1 (de) 2003-05-15
WO1997004779A1 (en) 1997-02-13
JPH11513021A (ja) 1999-11-09
EP0841929A1 (en) 1998-05-20
AU696390B2 (en) 1998-09-10
AU6626396A (en) 1997-02-26
EP0841929B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
MX9800922A (es) Quinolonas y su uso terapeutico.
MX9800921A (es) Quinolonas y su uso terapeutico.
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
AU3738393A (en) Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
AU5093593A (en) Inhibition of tumor metastasis via neutralization of tissue factor function
AU5788396A (en) Methods of inhibition or killing of cancer cells
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
AU5962396A (en) Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and deri vatives thereof
AU4473596A (en) Methods of human prostate cancer diagnosis
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU3400297A (en) Gm-csf administration for the treatment and prevention of recurrence of brain tumors
AU4808593A (en) Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
EP0656069A4 (en) CELL PROLIFERATION INHIBITORS, THEIR PRODUCTION AND USE.
AU6381996A (en) Inhibition of cancer cell growth, proliferation and metastas is using n,n'-dibenzyl-alpha,omega-diaminoalkanes
AU4202096A (en) The use of sertraline to treat cancer patients
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
AU642772B2 (en) Inhibitors for the formation of tumor necrosis factor, processes for the preparation thereof and the use thereof
AU5548694A (en) Peptide inhibitors of tyrosine kinases and therapeutic uses thereof
MX9708903A (es) Xantinas y su uso terapeutico.
AUPO851597A0 (en) Treatment of prostate cancer
AU7041194A (en) Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion
HK1019854A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees